US health regulators have approved a first-of-its-kind diabetes treatment, which combines two existing drugs in one tablet. The US Food and Drug Administration (FDA) has approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals’ Glyxambi (empagliflozin/linagliptin) tablets, as an adjunct to diet and exercise to improve glycemic control in adults …